



PAUL COHEN'S *Marijuana Hub*

A Division of Cohen Grassroots Research, Inc. www.cohengrassroots.com



Newsletter: September 29, 2015, Issue #192-- www.cohenresearch.com

Cohen Grassroots Research, Inc. is the Nation's Number #1 Micro Cap and Cannabis Research Firm
IR Research Reports (1,000+) - Distribution to 100s of thousands of investors

HOW TO MAKE MONEY IN THE MARIJUANA STOCK MARKET CANNABIS SCIENCE BRANDS ITS EXCITING MULTIPLE PRODUCTS

LOS ANGELES, CA, Sep 28, 2015 (Marketwired via COMTEX) -- Cannabis Science, Inc. (otc pink:CBIS), a U.S. Company specializing in cannabis-based pharmaceutical development, is ramping up its formal and informal Cancer studies in response to the National Cancer Institute initiatives to help save millions of preventable deaths each year by raising its Cancer Studies awareness and education about cancer. The Company is focused on persuading governments and individuals across the world to expand their preventive and therapeutic actions against Cancer and other critical ailments. Cannabis Science is highly motivated to accelerate the pace of its cancer drug development studies and is ramping up its new products distribution to the California market immediately through additional product releases and additional licensing deals in each state-by-state regulated market and its formal FDA initiatives.

"Our previous success with self-medicated patient usage is a great building block for us as our increasing requests for new products from self-medicating patients and dispensaries indicate. As we already know, affected people are looking for cannabinoid treatments for all types of acute and chronic illnesses. Cancer is just one of our major targets, and building from our previous success, we are ramping up production to start fulfilling that demand. Our patient-centered outcomes program, the Patient Access Center (PAC), will use extensive feedback from patients to inform our drug development efforts. In addition, the PAC will become a critical tool in our drug development cycle," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder Cannabis Science Inc., and the Cannabis Science Research Foundation. The Company has increased its product releases through the Cannabis Science Research Foundation (CSRF) <http://cannabisscienceresearchfoundation.org/> Cannabis Science has successfully released its first group of cannabinoids in California for test marketing and the positive results have been assessed as indicators to ramp up distribution and continue adding products, including pills, extracts, and creams, hiring of additional representatives and additional locations for a much larger products release. The CBIS Brand is currently being sold in multiple locations in California that are State licensed public and private cannabis dispensaries. Cancer is one of the leading causes of death worldwide and accounts for a large proportion of disability. The number of new cancer cases will rise to 22 million within the next two decades. More than 70% of these new cases will originate in Africa, Asia, and Central and South America; and 70% of the world's cancer deaths will also occur in these regions. The predicted increases will place an unsupportable burden on the health care systems of these regions and will add to the cost burden in developed countries. The recent Global Burden of Disease Study ranks a wide variety of cancers very highly in the leading causes of disability adjusted life years. Cancers of the respiratory tract (such as lung cancer), liver, stomach, and breast cancer rank highly in developed countries and are increasing at an accelerated rate in developing countries. As the incidence of cancers worldwide is increasing both prevention and effective efficient treatment strategies will become critically important. A number of research studies point to the effectiveness of cannabinoids in the treatment of cancer. It is imperative that anti-cancer cannabinoid drug development is accelerated and that effective treatments are brought to the market efficiently and rapidly.